Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic nicotinamide-expanded natural killer cells GDA-201

A preparation of allogeneic, nicotinamide (NAM)-expanded natural killer (NK) cells, with potential cytolytic and antineoplastic activities. Upon administration, the allogeneic NAM-expanded NK cells GDA-201 may lyse cancer cells. These cells also secrete pro-inflammatory cytokines, which further stimulate an anti-tumor immune response. Ex-vivo treatment with the vitamin B3 derivative NAM increases the in-vivo homing, retention and proliferation potential of the NK cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic NAM-expanded NK cells GDA-201
NAM NKs GDA-201
NAM-expanded allogeneic NK cells GDA-201
Code name:GDA 201
GDA-201
GDA201
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search